• IMA sites
    • IMAJ services
    • IMA journals
    • Follow us
    • Alternate Text Alternate Text
    עמוד בית
    Thu, 21.11.24

    Search results

    April 2020
    Sarit Appel MD, Orit Kaidar-Person MD, Yaacov Richard Lawrence MD MBBS MA MRCP, Maoz Ben-Ayun PhD, Tamar Katzman MPH BASc, Jair Bar MD PhD, Anat Mansano BA and Zvi Symon MD
    211-213 Abstract Full article
    November 2013
    D. Belkić and K. Belkić
    665-672 Abstract Full article
     With our increased understanding of cancer cell biology, molecular imaging offers a strategic bridge to oncology. This complements anatomic imaging, particularly magnetic resonance (MR) imaging, which is sensitive but not specific. Among the potential harms of false positive findings is lowered adherence to recommended surveillance post-therapy and by persons at increased cancer risk. Positron emission tomography (PET) plus computed tomography (CT) is the molecular imaging modality most widely used in oncology. In up to 40% of cases, PET-CT leads to changes in therapeutic management. Newer PET tracers can detect tumor hypoxia, bone metastases in androgen-sensitive prostate cancer, and human epidermal growth factor receptor type 2 (HER2)-expressive tumors. Magnetic resonance spectroscopy provides insight into several metabolites at the same time. Combined with MRI, this yields magnetic resonance spectroscopic imaging (MRSI), which does not entail ionizing radiation and is thus suitable for repeated monitoring. Using advanced signal processing, quantitative information can be gleaned about molecular markers of brain, breast, prostate and other cancers. Radiation oncology has benefited from molecular imaging via PET-CT and MRSI. Advanced mathematical approaches can improve dose planning in stereotactic radiosurgery, stereotactic body radiotherapy and high dose-rate brachytherapy. Molecular imaging will likely impact profoundly on clinical decision making in oncology. Molecular imaging via MR could facilitate early detection, especially in persons at high risk for specific cancers.

    About Imaj About Imaj Editorial Board
    Online Tools Submit a Manuscript Subscribing to IMAJ
    Contact Us Imaj Editorial 03-6100418 Fax 03-7519673 Service Center 03-6100471 Contact us by Online Form
    About IMA What is the Israeli Medical Association? IMA Site IMA Historical Background The IMA Vision
    Legal Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal or medical advice on any matter.
    The IMA is not responsible for and expressly disclaims liability for damages of any kind arising from the use of or reliance on information contained within the site.
    © All rights to information on this site are reserved and are the property of the Israeli Medical Association. Privacy policy

    2 Twin Towers, 35 Jabotinsky, POB 4292, Ramat Gan 5251108 Israel
    SLATECH - פיתוח אתרי אינטרנט ופורטלים ארגוניים המערכת פותחה על ידי חברת